

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Pfizer Health AB	06/30/2004
RECEIVING PARTY DATA	
Name:	Healon AB
Street Address:	Rapsgatan 7
City:	Uppsala
State/Country:	SWEDEN
Postal Code:	SE-751 36
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6030416
CORRESPONDENCE DATA	
Fax Number:	(714)247-8679
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	714.247.8516
Email:	rebecca.smith@amo-inc.com
Correspondent Name:	Advanced Medical Optics, Inc.
Address Line 1:	1700 E. St. Andrew Place
Address Line 4:	Santa Ana, CALIFORNIA 92705
NAME OF SUBMITTER:	Scott J. Catlin
Total Attachments: 10 source=Pfizer Health_Healon#page1.tif source=Pfizer Health_Healon#page2.tif source=Pfizer Health_Healon#page3.tif source=Pfizer Health_Healon#page4.tif source=Pfizer Health_Healon#page5.tif source=Pfizer Health_Healon#page6.tif source=Pfizer Health_Healon#page7.tif	

CH \$40.00 6030416

PATENT

REEL: 017083 FRAME: 0560

500074411

source=Pfizer Health_Healon#page8.tif
source=Pfizer Health_Healon#page9.tif
source=Pfizer Health_Healon#page10.tif

Patent Assignment Agreement

between

PFIZER HEALTH AB

and

HEALON AB

THIS PATENT ASSIGNMENT AGREEMENT is made and entered into on this ____ day of June 2004,

by and between

PFIZER HEALTH AB, a limited liability company duly established under the laws of Sweden, corporate identity number 556131-9608, having its registered office at Lindhagensgatan 100, 112 87 Stockholm, Sweden ("Seller"),

and

HEALON AB, a limited liability company duly established under the laws of Sweden, corporate identity number 556604-5422, having its registered office at 751 82 Uppsala, Sweden ("Buyer").

1. Introduction

1.1 On April 19, 2004, Seller and Buyer entered into an asset transfer agreement, as amended ("Asset Transfer Agreement"), under which Buyer agreed to purchase and acquire certain assets from Seller, including all of Seller's right, title and interest in and to the Patents (as defined below).

1.2 In view of the foregoing Seller and Buyer have agreed as follows.

2. Assignment

2.1 For the consideration set forth in the Asset Transfer Agreement the Seller hereby assigns to the Buyer the entire and exclusive right, title and interest of Seller in and to the patents and patent applications listed in Schedule A ("Patents").

2.2 The assignment of the rights in Section 2.1 is complete and includes all rights therein provided by international conventions and treaties and any and all rights of enforcement with respect to the Patents, including all rights to sue and recover for past infringements thereof, and any and all causes of action related thereto.

2.3 The Seller undertakes to execute and deliver, upon request and free of charge, any and all documents, forms and authorizations necessary for the registration of the assignment of the Patents with the relevant registration authorities (in all countries concerned).

- 2.4 The Seller shall pay all fees charged by the registration authorities in connection with the registration of the assignment of the Patents.

3. Miscellaneous

This Patent Assignment Agreement shall in all respects be deemed to be covered by Section 10.7 of the Asset Transfer Agreement on governing law and arbitration.

The parties hereto hereby cause this Patent Assignment Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

PFIZER HEALTH AB

HEALON AB

Patents

If any patent or patent application included in the list below is owned by Pharmacia Groningen B.V. such patent shall be deemed to be excluded from this Schedule.

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
1.	US 6558395 19104/01 <i>pending</i> EA 003591 00982028.3 <i>pending</i> P10016007-5 <i>pending</i> 2392393 <i>pending</i> 00816466.5 <i>pending</i> PV2002-1848 <i>pending</i> P200200269 <i>pending</i> 03104949.1 <i>pending</i> P0203854 <i>pending</i> IN/PCT/2002/00981 <i>pending</i> W-00200201530 <i>pending</i> 149571 <i>pending</i> 2001-541437 <i>pending</i> 2002-7006895 <i>pending</i> 2002/005359 <i>pending</i> 519003 <i>pending</i>	USA Australia Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova Russian Federation, Tajikistan, Turkmenistan EP Brazil Canada China Czech Republic Estonia Hong Kong Hungary India Indonesia Israel Japan South Korea Mexico New Zealand	Intraocular lens implanter	Pharmacia & Upjohn AB (today Pfizer Health AB)	PHIA-00002

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
	20022568 <i>pending</i> P-355905 <i>pending</i> 200203131-8 <i>pending</i> 9904338-2 <i>pending</i> 148879	Norway Poland Singapore Sweden Taiwan			
2.	US 4,764,360/2005 EP 0 202 257/2005 8405464-2 JP 1873877 CA 1256030/2006 MX 175155/2005	USA Germany, Spain, France, UK, Italy, Netherlands Sweden Japan Canada Mexico	Compositions of HYA and a polymeric colouring agent	Pharmacia AB (today Pfizer Health AB)	PII-00562
3.	US 5,681,825/2014	USA	High viscosity compositions of hyaluronic acid	Kabi Pharmacia AB (today Pfizer Health AB)	PII-00933
4.	US 6,537,795/2015 US 6,090,596 10/353891 <i>pending</i> EP 0 760 863 JP 500737/96 <i>pending</i> E221576 699404 CA 2191197 NZ 287583	USA USA USA Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, UK, Greece, Ireland, Luxembourg, Monaco, Netherlands, Portugal, Sweden, Italy Japan Austria Australia Canada New Zealand	Production of high molecular weight hyaluronic acid by super-encapsulated mutants of group C streptococci	Pharmacia AB (today Pfizer Health AB)	PII-01450

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
5.	US 6,368,585/2017 US 6,086,597/2017 EP 1023077 pending JP 3481952 2003-313532 <i>pending</i> AU 749522/2018 CA 2282757/2018 IL 131663 pending 01100778.7	USA USA Designated countries Japan Japan Australia Canada Israel Hong Kong	Compositions of 18-40 mg/ml sodium HYA having a molecular weight of 1×10^6	Pharmacia AB	PH-01742
6.	US 5,135,540 EP 0 404 929 <i>5025</i> E97795 JP 3083154 KR 162655 TW UM-66902 <i>Inactivated</i> 635542	USA Belgium, Austria, Switzerland, Germany, Denmark, Spain, France, Great Britain, Italy, Luxembourg, The Netherlands, Sweden Austria Japan South Korea Taiwan Australia	IOL with one piece haptic extending radially from the body	Pharmacia AB (today Pfizer Health AB)	PH-00861
7.	US 4,681,585 US 5,041,133 EP 0 161 764 JP 2069849	USA USA Germany, France, Great Britain, Italy, Sweden Japan	IOL with non-PMMA haptics stable for radiation and heat	Kabi Pharmacia AB (today Pfizer Health AB)	PH-00862
8.	US 467,789 <i>Inactivated</i> US 064,730 <i>Inactivated</i> EP 0 438 043	US US Switzerland, Germany, France, Great Britain, The Netherlands, Sweden	IOL with stretch strengthened haptics	Pharmacia AB (today Pfizer Health AB)	PH-00865

PATENT

REEL: 017083 FRAME: 0567

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
9.	US 5,429,838 EP 0 625 941 JP 3208428	USA Switzerland, Germany, Spain, France, Great Britain, Italy, The Netherlands, Sweden Japan	IOL-Capping	Pharmacia AB (today Pfizer Health AB)	PHI-001306
10.	US 4,995,879	USA	IOL with haptics drawn polymeric material with longitudinally oriented polymers	Kabi Pharmacia AB (today Pfizer Health AB)	PHI-01324
11.	US 5,375,611 JP 516924/94 <i>pending</i>	USA Japan	IOL with chemical modification to prevent from secondary cataract	Pharmacia AB (today Pfizer Health AB)	PHI-01329
12.	US 5,576,345 EP 0 696 917 JP 524162/94 <i>pending</i> CA 2,161,697	USA Denmark, Germany, Switzerland, Belgium, Austria, Spain, France, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, The Netherlands, Portugal, Sweden Japan Canada	Use of taxol to prevent secondary cataract	Pharmacia & Upjohn AB (today Pfizer Health AB)	PHI-01360
13.	US 5,376,115	USA	IOL with controlled vault following implantation	Pharmacia AB (today Pfizer Health AB)	PHI-01400
14.	US 5,549,669 JP 287245/94	USA Japan	IOL with non-symmetric haptic crosssection	Pharmacia AB (today Pfizer Health AB)	PHI-01518

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
15.	JP 533247/96 <i>pending</i> EP 96914498.9 <i>pending</i>	Japan EPO	HA-anthracyclin complex for preventing secondary cataract	Pharmacia & Upjohn AB (today Pfizer Health AB)	PII-01558
16.	US 6,011,082 US 6,251,965 US 09/876,572 <i>pending</i> US <i>pending</i> - appl. number missing EP 98924983.4 <i>pending</i> JP 502596/99 <i>pending</i>	USA USA USA USA EPO Japan	Silicon IOL with heparinized surface	Pharmacia AB (today Pfizer Health AB)	PII-01740

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
17.	US 6,030,416 CA 2,317,746 <i>pending</i> BR P19907757-4 <i>pending</i> AU 748650 JP 2000-531135 <i>pending</i> HU P0100231 <i>pending</i> KR 2000-7008881 <i>pending</i> CN 99802935.1 <i>pending</i> CZ PV2000-2905 <i>pending</i> MX 00077905 <i>pending</i> NO 2000 4050 <i>pending</i> NZ 505585 PL P342842 <i>pending</i> RU 2000123549/14 <i>pending</i> SG 74865 SK PV1128-2000 <i>pending</i> TR 2000/02259 <i>pending</i> IL 137807 <i>pending</i> HK 01109215.9 <i>pending</i> EP 1 056 415	USA Canada Brazil Australia Japan Hungary South Korea China Czech Republic Mexico Norway New Zealand Poland Russia Singapore Slovakia Turkey Israel Hong Kong Portugal, Luxembourg, Italy, Ireland, Greece, Great Britain, Cyprus, Denmark, Spain, Finland, Austria, Belgium, France, Switzerland, Germany, Monaco, The Netherlands, Sweden	IOLs made stretch crystallisable silicones	Pharmacia AB (today Pfizer Health AB)	PH-01810

No.	Registration/Application No.	Country	Description	Registered Owner	Former ref.
18.	US 6,036,891 EP 1 077 952 <i>51959</i> JP 2000-548311 <i>pending</i> ZA 2000/7285 NZ 507496 <i>pending</i> MX 0011063 <i>pending</i> KR 2000-7012524 <i>pending</i> HK 01108897.6 <i>pending</i> CN 99806023.2 <i>pending</i> CA 2,328,912 <i>pending</i> BR PI9910358-3 <i>pending</i> AU 754155	USA Finland, Austria, Belgium, Cyprus, Denmark, France, UK, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey Japan South Africa New Zealand Mexico South Korea Hong Kong China Canada Brazil Australia	IOIs from copolymerised UV blockers	Pharmacia AB (today Pfizer Health AB)	PII-01821
19.	US 6,066,172 US 6,361,561 US 10/013,692 <i>pending</i>	USA USA USA	Injectable IOIs from thermocurable silicones	Pharmacia AB (today Pfizer Health AB)	PII-01831
20.	US 6,399,734 US 10/134,710 <i>pending</i>	USA USA	Injectable IOIs from photocurable silicones	Pharmacia AB (today Pfizer Health AB)	PII-01839

PATENT

RECORDED: 01/30/2006

REEL: 017083 FRAME: 0571